Vadadustat

CHEMBL3646221 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
306.7 g/mol
LogP
2.5
Phase
4

Vadadustat is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stabilizes HIF-alpha subunits by blocking their hydroxylation and subsequent proteasomal degradation, thereby activating the physiological hypoxia response including increased erythropoietin production and red blood cell synthesis. It is used for the treatment of anemia associated with chronic kidney disease (CKD) in adults, offering an oral alternative to injectable erythropoiesis-stimulating agents (ESAs). Its mechanism mimics the body's natural adaptation to altitude and hypoxia.

Masse moléculaire

306,7000 g/mol

LogP

2,50

TPSA

99,50 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O

InChI

InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)

Molecular Formula

C14H11ClN2O4

HBD / HBA

3 / 5

Liaisons Rotatives

4

Atomes Lourds

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Vadadustat is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stabilizes HIF-alpha subunits by blocking their hydroxylation and subsequent proteasomal degradation, thereby activating the physiological hypoxia response including increased erythropoietin production and red blood cell synthesis. It is used for the treatment of anemia associated with chronic kidney disease (CKD) in adults, offering an oral alternative to injectable erythropoiesis-stimulating agents (ESAs). Its mechanism mimics the body's natural adaptation to altitude and hypoxia.

Yes, Vadadustat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3646221. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23634441. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.